This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: E72.4 (urea cycle disorder) | Special Copayment Reduction: V117 (rare disease) |
| B. Synonyms | OTC deficiency, OTCD, X-linked hyperammonemia, Ornithine carbamoyltransferase deficiency |
| C. Adult onset | Likelihood of first presentation in adulthood: considerable — in heterozygous female carriers, hyperammonemic encephalopathy may first appear in adulthood, triggered by factors such as a high-protein diet, surgery, infection or valproic acid use, and rarely diagnosis is delayed until adulthood even in mildly affected hemizygous males. |
| 1. History | 1962 first description by Russell et al. → 1980s cloning of the OTC gene → 1990s establishment of molecular diagnosis → 1993 attempt at AAV-based gene therapy → 2023 clinical trials of mRNA therapeutics under way. |
| 2. Causes | X-linked inheritance. OTC gene (Xp21.1) variants cause loss of urea cycle enzyme function → ammonia accumulation and increased orotic acid. |
| 3. Genetics | OTC gene: Xp21.1, 10 exons, 373 amino acids. X-linked inheritance. Severe in hemizygous males, variable phenotype in heterozygous females. More than about 400 pathogenic variants reported. |
| 4. General epidemiology | The most common urea cycle disorder. About 1 in 14,000~70,000 births. Estimated combined prevalence in males and females 1:14,000. Thousands registered worldwide. |
| 5. Pathophysiology | OTC enzyme deficiency → carbamoyl phosphate accumulation → diversion to the pyrimidine synthesis pathway (increased orotic acid) → urea cycle disorder → hyperammonemia → cerebral edema and neurological damage. |
| 6. Symptoms | Neonatal form: feeding refusal, lethargy, hyperventilation, seizures, coma. Late-onset form: headache, nausea, behavioral changes, seizures, reduced consciousness. Female carriers: anorexia with protein aversion, migraine. |
| 7. Signs | Markedly elevated blood ammonia, increased plasma glutamine, reduced citrulline, orotic aciduria. Respiratory alkalosis (hyperventilation). Brain MRI: diffuse edema, cortical signal abnormalities. |
| 8. Screening | Newborn screening: blood amino acid analysis (reduced citrulline). Urinary orotic acid measurement. Molecular genetic testing first when there is a family history. |
| 9. Diagnosis | Plasma amino acids (glutamine↑, citrulline↓), analysis of urinary ornithine metabolites, urinary orotic acid (↑), OTC gene analysis. Measurement of enzyme activity by liver biopsy (rarely needed). |
| 10. Treatment | Acute phase: protein restriction, intravenous glucose and lipids, ammonia scavengers (sodium benzoate·sodium phenylacetate, carglumic acid). Long term: low-protein diet, essential amino acid supplementation, citrulline, liver transplantation. |
| 11. Prognosis | Severe neonatal form: poor neurological prognosis without early liver transplantation. Late-onset form: cognitive impairment proportional to the number and duration of hyperammonemic episodes. Metabolic stabilization possible after liver transplantation. |
| 12. Prevention | Genetic counseling, molecular diagnosis of female carriers, prenatal diagnosis (CVS·amniocentesis). Avoidance of drugs that cause hyperammonemia, such as valproic acid. Restriction of high-protein diet. Early hospitalization protocol during infection. |
| 13. References | Summar ML et al. J Pediatr. 2013 and 9 other key references. |
Ornithine transcarbamylase deficiency (OTC deficiency) is one of the first urea cycle diseases to be systematically described. It first became clinically known in 1962 when Russell et al. reported a case of severe hyperammonemia in a newborn boy. At the time the etiology was not fully understood, but as research on urea cycle enzymes advanced through the 1960s~70s, deficiency of OTC enzyme activity was found to be the cause. In 1969, Levin et al. reported that a low-protein diet and keto acid supplementation led to clinical improvement in children with OTC enzyme deficiency, providing the basis for nutritional treatment.
Molecular biological progress was concentrated in the 1980s. In 1984, Horwich et al. cloned the OTC gene and confirmed its location on the short arm of the X chromosome (Xp21.1), which established the molecular basis of X-linked inheritance. Since 1986, numerous point mutations, deletions and insertions have been identified, and more than about 400 pathogenic variants are now registered in a database (OTCD mutation database). In the 1990s, polymerase chain reaction (PCR)-based direct sequencing made carrier diagnosis and prenatal diagnosis a reality.
A major turning point in the history of treatment was the introduction of agents promoting ammonia excretion. In 1979, Batshaw et al. first reported the effect of combined sodium benzoate and arginine, and a sodium phenylacetate combination product (Ammonul) subsequently received US FDA approval. From the late 1980s, liver transplantation was attempted in pediatric urea cycle diseases, and it was confirmed that metabolic correction close to biochemical cure is possible. In 1993, Wilson et al. first attempted gene therapy delivering the OTC gene to the liver with an adenovirus vector, but clinical trials were halted after the death of Jesse Gelsinger in 1999. This event led to a complete overhaul of safety protocols for clinical gene therapy. New approaches, including AAV8 vector-based gene therapy and mRNA therapeutics, are now in clinical trials, and in particular OTC mRNA therapy using the mRNA-LNP approach (code name mRNA-3927) is opening new horizons in rare disease treatment.
In Korea, the number of early diagnoses has increased since the 1990s, when blood amino acid analysis was introduced into newborn screening for metabolic disorders. Patient registration and treatment support are provided by the Korea Rare Disease Foundation and various medical institutions in Korea, and for patients who need liver transplantation, a collaborative care system with Korean liver transplant centers has been established. Medical expense support is provided through Special Copayment Reduction V117 registration.
OTC deficiency is an X-linked genetic disease caused by pathogenic variants in the OTC gene (short arm of the X chromosome, Xp21.1), resulting in loss or severe reduction of function of the enzyme ornithine transcarbamylase (OTC; EC 2.1.3.3), located in the mitochondrial matrix. In the urea cycle, the OTC enzyme catalyzes the reaction that combines carbamoyl phosphate and ornithine to produce citrulline. This reaction occurs only within the mitochondria and is a key step in the disposal of nitrogen (ammonia).
The types of OTC gene variants are very diverse. Point mutations (missense, nonsense), small deletions/insertions, splicing variants and large deletions have all been reported. Certain highly recurrent hotspot variants are known (e.g., regions adjacent to exons 4, 5 and 8), but the overall mutation spectrum is very heterogeneous. In some male patients, somatic mosaicism is observed, and the phenotype may be milder than expected.
Because of X-linked inheritance, hemizygous males generally show a severe phenotype. In contrast, heterozygous female carriers show a broad range of phenotypes, from asymptomatic to severe encephalopathy, depending on the X-inactivation (lyonization) pattern. Severe clinical manifestations are possible in females as well owing to skewed X-inactivation, in which case a treatment approach similar to that for male patients is needed.
About 20% of patients are reported to have de novo variants without a family history. These de novo variants arise at the maternal germ cell stage or during the early cleavage of the zygote, so clinical suspicion is important even without a family history. Drugs such as valproic acid and asparaginase suppress urea cycle function and are important triggers of hyperammonemia in patients with OTC gene variants. In clinical practice, OTC deficiency must always be considered in the differential diagnosis of hyperammonemia occurring suddenly after administration of certain drugs.
The OTC gene is located on the short arm of the X chromosome (Xp21.1), is about 73 kb in total size and consists of 10 exons. The encoded preprotein is 354 amino acids long, and after signal peptide cleavage the mature protein of 322 amino acids forms a homotrimer in the mitochondrial matrix and exhibits enzymatic activity. Crystallographic studies have shown that each monomer of the OTC enzyme consists of a carbamoyl phosphate-binding domain and an ornithine-binding domain.
The mode of inheritance is X-linked hemizygous. Theoretically, 50% of boys may be affected and 50% of girls may be carriers. However, because clinical manifestations in heterozygous females vary greatly due to X-inactivation (lyonization), confirmation by biochemical and genetic testing is needed in female carriers as well. Analysis of the X-inactivation ratio by liver biopsy is performed in some clinical settings, but it can be adequately replaced by molecular genetic testing.
More than about 400 pathogenic OTC variants have been reported to date and are compiled in the OTCD Mutation Database (otcd.gene.sickkids.ca). The association between variant type and clinical severity is partly established. Missense variants affecting the active site tend to abolish enzyme activity almost completely and cause the severe neonatal form, while variants in poorly conserved regions or splicing variants often retain residual enzyme activity and show a late-onset phenotype.
Carrier diagnosis and prenatal diagnosis are performed by molecular genetic testing. When the family variant is known, targeted variant analysis is performed; when it is not, next-generation sequencing (NGS) of the entire OTC gene is performed. Prenatal diagnosis uses fetal DNA obtained by chorionic villus sampling (CVS, 11~14 weeks) or amniocentesis (15~20 weeks). Excluding affected embryos through preimplantation genetic testing (PGT) is also possible, but availability varies with national and hospital policies.
OTC deficiency is the most common single disease among all urea cycle disorders (UCDs), accounting for about 50~60% of all UCDs. Birth frequency varies by study from 1 in 14,000 to 70,000 births, but large cohort analyses such as in the United States report about 1:14,000~1:40,000. Although it is X-linked, heterozygous female carriers can also be clinically affected, so the actual number of patients should be estimated by combining hemizygous males and symptomatic heterozygous females.
Regional and ethnic differences in frequency have not been clearly established, but diagnostic rates are higher in countries with established newborn screening systems. In the US national UCD cohort study (UCDC Longitudinal Study), patients with OTC deficiency make up the largest share, with several hundred or more registered and being followed as of 2022. In the European rare disease network (MetabERN), OTC deficiency is also classified as a top-priority disease for management.
In terms of sex distribution, hemizygous males are mostly diagnosed with severe presentation in the neonatal period or infancy. The proportion of heterozygous female carriers who show symptoms is variously reported as 15~40% depending on the study, and many of them are first diagnosed in adulthood with a hyperammonemic episode. In such adult-onset female carriers, nonspecific symptoms (headache, behavioral changes, altered consciousness) often lead to misdiagnosis as psychiatric or neurological disease.
Korean epidemiological data are limited, but in the Rare Disease Helpline and Health Insurance Review & Assessment Service (HIRA) statistics, OTC deficiency is classified as a major disease group among inborn errors of metabolism. In Korea too, early diagnoses have been increasing since the expansion of newborn tandem mass spectrometry (MS/MS) screening. Medical cost reduction benefits are provided through Special Copayment Reduction V117 registration, and a national support program operates for severely affected pediatric patients who need liver transplantation.
The urea cycle is a metabolic pathway spanning the mitochondria and cytosol of hepatocytes that converts ammonia into nontoxic urea. Normally, ammonia generated from amino acid breakdown, intestinal bacterial metabolism, muscle protein catabolism and other sources is delivered to the liver in the form of glutamate and glutamine and, via the urea cycle in the liver, excreted by the kidneys as urea. In the second step of the urea cycle, the OTC enzyme combines carbamoyl phosphate and ornithine within the mitochondria to produce citrulline. When OTC enzyme activity is lost, this step is blocked.
When the OTC enzyme is deficient, carbamoyl phosphate (CP) accumulates in the mitochondria, and CP that leaks into the cytosol is diverted to the pyrimidine synthesis pathway, markedly increasing orotic acid production. This becomes the characteristic biochemical marker of OTC deficiency: increased urinary orotic acid. At the same time, citrulline synthesis decreases, impairing the entire downstream urea cycle, and as a result ammonia accumulates in the blood and brain tissue.
Hyperammonemia has direct and severe toxicity to the central nervous system. Ammonia readily crosses the blood-brain barrier and increases glutamine synthesis in astrocytes, causing osmotic edema. Excess glutamine accumulation opens the mitochondrial permeability transition pore (mPTP), damaging astrocytes, and also affects GABA-A and NMDA receptor activity, causing seizures and impaired consciousness. Cerebral edema leads to raised intracranial pressure and can result in brain herniation and death.
In chronic hyperammonemia, along with impaired glutamine metabolism, reduced reuptake of glutamate (an excitatory neurotransmitter) sustains neuronal excitotoxicity, and impaired white matter myelination develops, causing cognitive and developmental disabilities. Long-term recurrent episodic hyperammonemia is known to accumulate irreversible damage to the cerebral cortex and basal ganglia. The degree of this neurotoxicity is determined by the peak concentration and duration of hyperammonemia and the age at which it occurs (the developing brain is more vulnerable).
The clinical symptoms of OTC deficiency are divided by timing of presentation and severity into neonatal-onset and late-onset forms. Severity depends mainly on residual OTC enzyme activity and variant type, and the X-inactivation pattern additionally influences clinical manifestation in females.
Symptoms of the neonatal form (severe, hemizygous males): after a normal birth, feeding refusal and lethargy begin within 24~72 hours, then rapidly progress to hyperventilation (a response to ammonia causing respiratory alkalosis), vomiting, hypotonia and seizures. If treatment is delayed, the infant falls into a coma and respiratory failure develops due to brainstem dysfunction. At this stage, blood ammonia often rises above 1,000 µmol/L (normal < 50 µmol/L). Differentiation from neonatal sepsis, heart disease and other metabolic disorders is needed.
Symptoms of the late-onset form (mildly affected males and female carriers): may present at various times from infancy to adulthood. Headache, nausea, vomiting, drowsiness and behavioral changes after protein-rich meals are the initial symptoms. Recurrent vomiting, loss of appetite and protein aversion (a tendency to instinctively avoid protein intake) are characteristic. In severe cases, the condition progresses to seizures, clouding of consciousness and hyperammonemic encephalopathy. Metabolic stresses such as valproic acid, high-protein infusions, infection, surgery and childbirth trigger or worsen episodes.
Symptoms in female carriers: the spectrum is broad, ranging from no symptoms to recurrent headache, migraine, anorexia, protein-avoidant eating habits, recurrent vomiting episodes, attention deficit and intermittent changes in consciousness. In clinical practice it is not uncommon for hyperammonemic encephalopathy to appear for the first time after childbirth or after taking valproic acid, leading to the diagnosis. In such cases, patients present to the emergency department with sudden reduced consciousness and are first evaluated for acute encephalopathy, after which OTC deficiency is identified on biochemical testing.
Symptoms in the chronic course: in late-onset patients who have not been adequately treated or patients who have experienced recurrent episodes, cognitive decline, attention deficit, learning disability and behavioral abnormalities accumulate. Some may have hepatomegaly and elevated liver enzymes, but progression to cirrhosis is rare. Growth retardation may also occur as a result of chronic protein-restricted diet and recurrent episodes.
The physical signs of OTC deficiency vary with the timing of presentation and severity of the disease. Signs during acute hyperammonemic episodes and signs in the chronic course should be recognized separately.
Signs of acute hyperammonemia: hyperventilation, a reflection of central respiratory abnormality (respiratory alkalosis), is characteristic in patients with hyperammonemia. Hypotonia, reduced or increased reflexes, abnormal eye movements and abnormal posturing (decerebrate·decorticate posturing) are observed in severe cases. Seizures occur intermittently or persistently and may be difficult to control. The level of consciousness is assessed with the Glasgow Coma Scale (GCS) and may progress to coma. With raised intracranial pressure, pupillary abnormalities and papilledema may appear.
Laboratory findings: markedly elevated blood ammonia (neonatal form > 300 µmol/L, late-onset form 100~500 µmol/L). Plasma amino acid analysis: markedly increased glutamine, increased alanine, reduced citrulline (< 10 µmol/L is characteristic). Urinary orotic acid: markedly increased (measured by GC-MS or HPLC). Blood gases: respiratory alkalosis → mixed with metabolic acidosis in severe cases. Serum liver enzymes (AST/ALT) may be mildly elevated. Platelet and coagulation tests may show abnormalities in the acute phase.
Brain imaging findings: in acute hyperammonemic encephalopathy, head MRI shows diffuse cerebral edema and increased T2 signal in the cortex, basal ganglia and thalamus. After recurrent episodes or a severe acute phase, cortical atrophy and white matter signal abnormalities may remain as persistent changes. MR spectroscopy (MRS) shows an increased glutamine/glutamate complex peak. EEG may show diffuse slow-wave abnormalities, triphasic waves and epileptiform discharges.
Chronic findings: in patients under treatment the physical examination may be normal, but after recurrent episodes, cognitive decline, impaired concentration and subtle neurological abnormalities (fine motor abnormalities, delayed language development) may persist. Hepatomegaly and liver function abnormalities are observed in some, but severe liver fibrosis or cirrhosis is rare.
Screening for OTC deficiency is divided into newborn screening and testing of at-risk groups based on family history. Population-wide screening is carried out by analysis of newborn blood amino acids and acylcarnitines using tandem mass spectrometry (MS/MS). In OTC deficiency, a reduced plasma citrulline concentration is the characteristic marker, but the sensitivity and specificity of this marker alone are not complete, and false negatives also occur.
Limitations of newborn screening: late-onset male patients and heterozygous female carriers may show normal blood amino acid results on newborn screening. Therefore, a negative screening test does not completely exclude OTC deficiency. In newborns with a family history, molecular genetic testing is recommended before screening tests.
Urinary orotic acid testing: a markedly increased orotic acid on urine organic acid analysis (GC-MS or HPLC) during an acute hyperammonemic episode strongly suggests OTC deficiency. This is useful for differentiating it from other urea cycle diseases (carbamoyl phosphate synthetase I deficiency, etc.). However, orotic aciduria may normalize between episodes, so repeat measurement is needed when clinically suspected.
Family history-based screening: direct OTC gene testing is recommended for the families of confirmed patients, especially maternal female relatives (mother, sisters, maternal aunts, maternal grandmother, etc.). Women confirmed as carriers should receive preconception genetic counseling and establish a prenatal diagnosis plan.
OTC deficiency is confirmed by combining biochemical testing and molecular genetic testing. The approach can be divided into emergency diagnosis in patients with acute hyperammonemia and elective diagnosis in stable patients or at-risk groups.
Measurement of blood ammonia: the first step in diagnosis. Normal values are < 50 µmol/L in adults and < 100 µmol/L in newborns and infants. As soon as hyperammonemia is confirmed, the underlying disease must be differentiated by plasma amino acid analysis and urine organic acid analysis.
Quantitative plasma amino acid analysis: increased glutamine, increased alanine, reduced citrulline (< 10 µmol/L) and normal argininosuccinic acid are characteristic of OTC deficiency. These findings are used to distinguish it from CPSI deficiency (reduced citrulline, normal orotic acid).
Urine organic acid and amino acid analysis: markedly increased orotic acid. Rarely, orotidine is also increased. Because orotic acid may normalize between episodes, confirmation is sometimes made by a protein loading test, but this carries a risk of inducing hyperammonemia and should be performed only at specialist centers.
OTC gene analysis: the standard for confirmation. Next-generation sequencing (NGS)-based analysis of the entire OTC gene or sequencing of exons and exon-intron boundaries. If no variant is detected, MLPA analysis to detect exon deletions/duplications is added. Genetic test results are also used for carrier counseling and prenatal diagnosis.
Measurement of enzyme activity: OTC enzyme activity can be measured directly in liver biopsy tissue, but because most cases can now be confirmed by molecular genetic testing, the role of liver biopsy has diminished. It is considered only for mosaic male patients or cases in which genetic testing fails to find a variant.
Treatment of OTC deficiency is divided into emergency management of acute hyperammonemia and long-term metabolic management. Collaboration of a multidisciplinary team (metabolic medicine, dietitian, genetic counselor, neurology, surgery) is essential.
Emergency management of acute hyperammonemia: immediate cessation of protein intake (short term, 24~48 hours). Intravenous glucose and lipids are given to suppress catabolism and supply energy (glucose 10~12 mg/kg/min, lipids 1~2 g/kg/day). Administration of agents promoting ammonia excretion: sodium benzoate (250 mg/kg/day by continuous intravenous infusion) + sodium phenylacetate (250 mg/kg/day). Citrulline or arginine supplementation. If blood ammonia is > 500 µmol/L or there is no response to treatment, hemodialysis must be performed promptly. Peritoneal dialysis is not recommended because of its low efficiency.
Long-term metabolic management: low-protein diet (protein restriction, combining natural protein with an essential amino acid mixture). Oral citrulline (1~2 mmol/kg/day) or arginine supplementation to preserve residual urea cycle capacity. Oral agents promoting ammonia excretion: sodium benzoate or glycerol phenylbutyrate (Ravicti). Supplementation of micronutrients such as vitamin B6 and zinc is sometimes needed.
Liver transplantation: the definitive biochemical treatment for OTC deficiency; after transplantation, urea cycle function normalizes and ammonia episodes disappear. In boys with the severe neonatal form, early transplantation (at 3~6 months of age) while neurological damage is minimal is recommended. Liver transplantation does not reverse neurological damage that has already occurred, but it prevents further damage. Living-donor split liver transplantation can be applied in children.
New treatments: mRNA therapeutics (mRNA-LNP approach, delivering OTC mRNA to hepatocytes) are in clinical trials, and AAV8 vector gene therapy is also at the preclinical/early clinical stage. Carglumic acid (N-carbamylglutamate) is a CPSI activator used in some UCDs, but its role in OTC deficiency is limited.
The prognosis of OTC deficiency is determined by the timing of presentation, the degree and duration of hyperammonemia, the time at which treatment begins and whether liver transplantation is performed. Overall, the prognosis is worst in severe neonatal-form patients and relatively favorable in the late-onset form and in female carriers.
Prognosis of severe neonatal-form patients: without treatment, death within days is inevitable. The peak level of initial hyperammonemia and the duration of coma are the most important factors determining the neurological prognosis. With blood ammonia of 500 µmol/L or more and coma lasting > 24 hours, survivors are likely to be left with severe neurodevelopmental disability. Relatively better neurodevelopmental outcomes have been reported with early diagnosis (newborn screening), immediate metabolic management and early liver transplantation (3~6 months), but normal development is not fully guaranteed.
Prognosis of late-onset patients and female carriers: if hyperammonemic episodes are adequately prevented and long-term metabolic management is adhered to, cognitive function and quality of life can be largely maintained. The number of episodes and cumulative exposure to neurotoxicity are the key predictors of long-term cognitive outcome. After liver transplantation, hyperammonemic episodes disappear and dietary restrictions are greatly relaxed, markedly improving quality of life. Long-term survival of liver transplant patients is generally good based on transplant outcomes in pediatric metabolic diseases (5-year survival 85~90%).
Neurocognitive outcomes: in patients who have experienced recurrent hyperammonemia, reduced IQ, attention deficit hyperactivity disorder (ADHD), impaired executive function and delayed language development may persist. Mild cognitive decline is also reported in female carriers whose diagnosis was delayed until adulthood. Cognitive rehabilitation and special education programs help patients with neurological damage. Neuropsychological assessments are performed regularly to follow cognitive changes.
Prevention strategies for OTC deficiency are organized into primary prevention of genetic risk, secondary prevention of hyperammonemic episodes and tertiary prevention to inhibit the progression of neurological damage.
Primary prevention — genetic counseling and prenatal diagnosis: molecular genetic testing of female carriers is performed in families with a confirmed OTC variant. When planning a pregnancy, genetic counseling identifies the risk of having a boy with OTC deficiency (for a heterozygous woman, 50% of sons and 50% of daughters are carriers), and prenatal diagnosis (CVS or amniocentesis) or preimplantation genetic testing (PGT) can be chosen. Genetic counseling before the family expands is needed in the case of de novo mutations as well.
Secondary prevention — avoidance of triggers and emergency protocols: all patients with OTC deficiency and symptomatic carriers must recognize drugs that affect ammonia metabolism, such as valproic acid, asparaginase and high-dose salicylates, as contraindicated. A high-protein diet (protein-rich meats, high-protein supplements) is avoided, and the prescribed low-protein diet and amino acid supplements are adhered to. In metabolic stress situations such as infection, surgery, childbirth and prolonged fasting, patients are hospitalized for intensive metabolic monitoring and preventive administration (intravenous glucose, agents promoting ammonia excretion). An emergency protocol letter is shared with medical institutions.
Tertiary prevention — prevention of neurological damage and regular follow-up: metabolic status is monitored by regular measurement of blood ammonia and analysis of plasma amino acids and urinary orotic acid. Cognitive function, neurodevelopment and neuropsychological assessments are performed 1~2 times a year to establish learning support and rehabilitation plans. Even after liver transplantation, follow-up of renal function related to immunosuppressants, infection prevention and ongoing neurocognitive monitoring are needed. Patient education and strengthened self-management skills enable early recognition of and rapid response to episodes.
Summar ML, Mew NA. Inborn errors of metabolism with hyperammonemia: urea cycle defects and related disorders. Pediatr Clin North Am. 2018;65(2):231-246. DOI: 10.1016/j.pcl.2017.11.004. PMID: 29502912.
Batshaw ML, Tuchman M, Summar M, Seminara J. A longitudinal study of urea cycle disorders. Mol Genet Metab. 2014;113(1-2):127-130. DOI: 10.1016/j.ymgme.2014.08.001. PMID: 25135652.
Häberle J, Boddaert N, Burlina A, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders. Orphanet J Rare Dis. 2012;7:32. DOI: 10.1186/1750-1172-7-32. PMID: 22642880.
Lichter-Konecki U, Caldovic L, Morizono H, et al. Ornithine Transcarbamylase Deficiency. In: Adam MP, et al., eds. GeneReviews®. NCBI Bookshelf. 2013 Aug 29 [updated 2022]. PMID: 20301371.
Ah Mew N, Simpson KL, Gropman AL, et al. Urea cycle disorders overview. In: Adam MP, et al., eds. GeneReviews®. NCBI Bookshelf. 2003 [updated 2023]. PMID: 20301396.
Prasad AN, Breen JC, Ampola MG, Rosman NP. Argininosuccinic aciduria: a treatable genetic metabolic disease. Pediatr Neurol. 1997;16(1):7-14. PMID: 9044399.
Feillet F, Häberle J, Haigis M, et al. Guidelines for management of patients with urea cycle disorders. J Inherit Metab Dis. 2023;46(5):1011-1035. DOI: 10.1002/jimd.12619. PMID: 37408494.
Deignan JL, Cederbaum SD, Grody WW. Contrasting features of urea cycle disorders in human patients and knockout mouse models. Mol Genet Metab. 2008;93(1):7-14. DOI: 10.1016/j.ymgme.2007.08.123. PMID: 17933572.
Häberle J, Burlina A, Chakrapani A, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders: first revision. J Inherit Metab Dis. 2019;42(6):1192-1230. DOI: 10.1002/jimd.12100. PMID: 30982989.
Kim IK, Niemi AK, Venick R, et al. Liver transplantation in urea cycle disorders: analysis of the United Network for Organ Sharing database. Pediatr Transplant. 2015;19(4):398-403. DOI: 10.1111/petr.12444. PMID: 25652078.